Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

January 2012 - FRMC

01/25/2012

Tim Casey

Tim Casey
Orlando—Patients with left ventricular systolic dysfunction who visited pharmacists did not experience a significant decrease in death or hospital admissions compared with a group that did not have pharmacist intervention, according to a...
Orlando—Patients with left ventricular systolic dysfunction who visited pharmacists did not experience a significant decrease in death or hospital admissions compared with a group that did not have pharmacist intervention, according to a...
Orlando—Patients with left...
01/25/2012
First Report Managed Care
01/25/2012

Eileen Koutnik-Fotopoulos

Eileen Koutnik-Fotopoulos
Orlando—Two commonly used anticlotting regimens—abciximab with unfractionated heparin and bivalirudin—were similarly effective in preventing death, subsequent myocardial infarction (MI), or need for further revascularization in patients with...
Orlando—Two commonly used anticlotting regimens—abciximab with unfractionated heparin and bivalirudin—were similarly effective in preventing death, subsequent myocardial infarction (MI), or need for further revascularization in patients with...
Orlando—Two commonly used...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
Orlando—A phase 3, randomized, double-blind, placebo-controlled trial found that patients with high triglyceride levels who took 4 or 2 g/day of AMR101 had a significant reduction in median placebo-adjusted triglyceride levels from baseline...
Orlando—A phase 3, randomized, double-blind, placebo-controlled trial found that patients with high triglyceride levels who took 4 or 2 g/day of AMR101 had a significant reduction in median placebo-adjusted triglyceride levels from baseline...
Orlando—A phase 3, randomized,...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
San Diego—A retrospective cohort analysis of medical claims databases found that the costs associated with treating patients with chronic myeloid leukemia (CML) were substantial, with the majority of the expenses attributed to...
San Diego—A retrospective cohort analysis of medical claims databases found that the costs associated with treating patients with chronic myeloid leukemia (CML) were substantial, with the majority of the expenses attributed to...
San Diego—A retrospective cohort...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
San Diego—Patients with chronic myeloid leukemia (CML) or Philadelphia-positive chromosome acute lymphoblastic leukemia (Ph+ALL) who are resistant or intolerant to popular tyrosine kinase inhibitors (TKIs) may soon have another option to...
San Diego—Patients with chronic myeloid leukemia (CML) or Philadelphia-positive chromosome acute lymphoblastic leukemia (Ph+ALL) who are resistant or intolerant to popular tyrosine kinase inhibitors (TKIs) may soon have another option to...
San Diego—Patients with chronic...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
San Diego—An updated analysis of two phase 3 trials found that ruxolitinib had a significant overall survival advantage across a variety of subgroups and that the oral drug was associated with improvement in health-related quality of life and...
San Diego—An updated analysis of two phase 3 trials found that ruxolitinib had a significant overall survival advantage across a variety of subgroups and that the oral drug was associated with improvement in health-related quality of life and...
San Diego—An updated analysis of...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
San Diego—A prospective, longitudinal, observational study found that the health-related quality of life (HRQOL) in patients with chronic lymphocytic leukemia (CLL) did not differ based on age. In addition, the most common type of first-line...
San Diego—A prospective, longitudinal, observational study found that the health-related quality of life (HRQOL) in patients with chronic lymphocytic leukemia (CLL) did not differ based on age. In addition, the most common type of first-line...
San Diego—A prospective,...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
San Diego—Patients with relapsed and refractory multiple myeloma who took a combination of bortezomib and vorinostat had a significantly longer progression-free survival and time to progression compared with a group that took bortezomib...
San Diego—Patients with relapsed and refractory multiple myeloma who took a combination of bortezomib and vorinostat had a significantly longer progression-free survival and time to progression compared with a group that took bortezomib...
San Diego—Patients with relapsed...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
San Diego—According to a cross-sectional survey of patients with chronic myeloid leukemia (CML) in the United States and Europe, patients who took nilotinib were significantly more likely to have difficulty adhering to their treatment regimen...
San Diego—According to a cross-sectional survey of patients with chronic myeloid leukemia (CML) in the United States and Europe, patients who took nilotinib were significantly more likely to have difficulty adhering to their treatment regimen...
San Diego—According to a...
01/25/2012
First Report Managed Care
01/25/2012

Tim Casey

Tim Casey
San Diego—Patients with limited-stage Hodgkin’s lymphoma who received a standard chemotherapy regimen alone had longer overall survival compared with a group that received a combination of chemotherapy and radiation treatment or radiation...
San Diego—Patients with limited-stage Hodgkin’s lymphoma who received a standard chemotherapy regimen alone had longer overall survival compared with a group that received a combination of chemotherapy and radiation treatment or radiation...
San Diego—Patients with...
01/25/2012
First Report Managed Care

Advertisement

Advertisement

Advertisement